Onco-hematology
RCT: In patients with chronic myeloid leukemia in chronic phase resistant/intolerant to ≥2 tyrosine kinase inhibitors, Asciminib resulted in better disease response compared to Bosutinib.
28 Jan, 2022 | 08:00h | UTCNews Release: Asciminib Superior to Bosutinib in Chronic-Phase CML – ASH Clinical News
RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.
21 Jan, 2022 | 09:28h | UTCPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.
19 Jan, 2022 | 08:22h | UTCNaive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology
Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
Best Practice Recommendations: Management of adults and children receiving CAR T-cell therapy.
12 Jan, 2022 | 08:31h | UTC
Hematology, the ASH Education Program – series of review articles with clinical cases published annually by the American Society of Hematology.
13 Dec, 2021 | 08:45h | UTCHomepage: Hematology, the ASH Education Program
Non-inferiority randomized trial showed radiotherapy can be safely omitted in many children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma.
10 Dec, 2021 | 10:04h | UTC
RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.
7 Dec, 2021 | 08:37h | UTC
Review: Castleman disease.
26 Nov, 2021 | 09:49h | UTCCastleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Castleman Disease (if the link is paywalled, try this one)
Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia.
14 Nov, 2021 | 19:32h | UTCNews release: Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy – NIH News Releases
Commentary on Twitter
Clinical trial showed that pediatric patients with acute promyelocytic leukemia (APL) have very high cure rates with treatment regimen that uses targeted therapy and no cytotoxic chemotherapy for standard risk APL or limited anthracycline for high risk APL https://t.co/V3mahhIb6Y
— JAMA Oncology (@JAMAOnc) November 11, 2021
Cluster RCT: In older adults with advanced cancer, a geriatric assessment program reduced the toxic effects of cancer treatment.
5 Nov, 2021 | 09:48h | UTCRelated:
Perspective: A Cancer Care Approach Tailored to The Elderly May Have Better Results
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/rochgerionc/status/1456046017766375425
CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.
4 Nov, 2021 | 10:06h | UTCCommentaries:
Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN
Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News
ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
2 Nov, 2021 | 02:51h | UTC
ASCO Guideline: Management of immune-related adverse events in patients treated with Chimeric Antigen Receptor T-Cell Therapy.
2 Nov, 2021 | 02:47h | UTC
RCT: Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma.
28 Oct, 2021 | 09:53h | UTC
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
21 Oct, 2021 | 10:06h | UTCRelated:
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.
14 Oct, 2021 | 09:44h | UTC
State of the Art Review: Advances in acute myeloid leukemia.
8 Oct, 2021 | 10:05h | UTCAdvances in acute myeloid leukemia – The BMJ
Commentary on Twitter
Acute myeloid leukemia is an uncommon but potentially catastrophic diagnosis.
This review looks at new updates in our understanding of the biology of acute myeloid leukemia, its genetic and environmental risk factors, and new treatment options https://t.co/ugaCeYkqSH
— The BMJ (@bmj_latest) October 6, 2021
Series from the Lancet journals: Hematological malignancies in older people.
6 Oct, 2021 | 08:47h | UTCHomepage: Haematological malignancies in older people – The Lancet Haematology
Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)
A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)
Frailty assessment in the care of older people with haematological malignancies
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)
Podcast: Neutropenic Fever.
28 Sep, 2021 | 08:52h | UTC#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders
Guideline: Acute abdomen in the immunocompromised patient.
16 Aug, 2021 | 01:00h | UTC
Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.
13 Aug, 2021 | 09:47h | UTC
Commentary on Twitter
Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease https://t.co/BXkUQGMmbO via @JAMAOnc part of @JAMANetwork
— Tom Ollila (@OllilaTom) August 11, 2021
Guideline: Laboratory detection and initial diagnosis of monoclonal gammopathies.
6 Aug, 2021 | 09:56h | UTC
European PanCare Follow Up Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer.
1 Aug, 2021 | 23:59h | UTC